Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

BrainStorm initiates phase II study of MSC-NTF cells in progressive MS

March 14, 2019

AbbVie initiates phase I study of alpha-synuclein-targeting antibody ABBV-0805 for Parkinson's

March 14, 2019

Development of a novel, selective, kappa-opioid receptor antagonist

March 14, 2019

RGC-32 as new target in chronic multiple sclerosis

March 14, 2019

Identification of pyrrolidine amide derivatives as novel N-acylethanolamine acid amidase inhibitors

March 14, 2019

ACAM is a potential molecular target for treating multiple sclerosis

March 14, 2019

Gene editing alleviates AD deficits in mouse models

March 14, 2019

Identification of a novel target for the development of stroke treatments

March 14, 2019

New mouse model of multiple sclerosis points to NLRX1 as a treatment target

March 13, 2019

Friedrich-Alexander-Universitaet Erlangen-Nuernberg and collaborators patent MOR agonists

March 13, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.